NIGHTHAWK BIOSCIENCES INC (NHWK) Stock Fundamental Analysis

NYSEARCA:NHWK • US42237K4094

0.4135 USD
+0.03 (+8.96%)
At close: Feb 5, 2024
0.4299 USD
+0.02 (+3.97%)
After Hours: 2/5/2024, 8:04:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

NHWK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. Both the profitability and financial health of NHWK have multiple concerns. NHWK is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NHWK has reported negative net income.
  • In the past year NHWK has reported a negative cash flow from operations.
NHWK Yearly Net Income VS EBIT VS OCF VS FCFNHWK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -74.32%, NHWK is doing worse than 71.89% of the companies in the same industry.
  • With a Return On Equity value of -143.11%, NHWK is not doing good in the industry: 65.82% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -74.32%
ROE -143.11%
ROIC N/A
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
NHWK Yearly ROA, ROE, ROICNHWK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

  • With a decent Gross Margin value of 28.70%, NHWK is doing good in the industry, outperforming 76.43% of the companies in the same industry.
  • NHWK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NHWK Yearly Profit, Operating, Gross MarginsNHWK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • NHWK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NHWK has been increased compared to 1 year ago.
  • Compared to 1 year ago, NHWK has a worse debt to assets ratio.
NHWK Yearly Shares OutstandingNHWK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
NHWK Yearly Total Debt VS Total AssetsNHWK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -6.72, we must say that NHWK is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -6.72, NHWK is doing worse than 72.22% of the companies in the same industry.
  • NHWK has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • NHWK has a worse Debt to Equity ratio (0.25) than 71.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z -6.72
ROIC/WACCN/A
WACC10.89%
NHWK Yearly LT Debt VS Equity VS FCFNHWK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M 100M

2.3 Liquidity

  • NHWK has a Current Ratio of 0.99. This is a bad value and indicates that NHWK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NHWK has a Current ratio of 0.99. This is amonst the worse of the industry: NHWK underperforms 90.40% of its industry peers.
  • A Quick Ratio of 0.99 indicates that NHWK may have some problems paying its short term obligations.
  • NHWK has a worse Quick ratio (0.99) than 89.23% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.99
NHWK Yearly Current Assets VS Current LiabilitesNHWK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • NHWK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.47%.
  • Looking at the last year, NHWK shows a very strong growth in Revenue. The Revenue has grown by 147.78%.
  • Measured over the past years, NHWK shows a very strong growth in Revenue. The Revenue has been growing by 33.23% on average per year.
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%

3.2 Future

  • NHWK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.45% yearly.
  • NHWK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 71.98% yearly.
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NHWK Yearly Revenue VS EstimatesNHWK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
NHWK Yearly EPS VS EstimatesNHWK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NHWK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NHWK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NHWK Price Earnings VS Forward Price EarningsNHWK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NHWK Per share dataNHWK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • NHWK's earnings are expected to grow with 18.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.97%
EPS Next 3Y18.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NHWK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NIGHTHAWK BIOSCIENCES INC

NYSEARCA:NHWK (2/5/2024, 8:04:02 PM)

After market: 0.4299 +0.02 (+3.97%)

0.4135

+0.03 (+8.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)03-29
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap36.34M
Revenue(TTM)2.23M
Net Income(TTM)-51.95M
Analysts43.33
Price Target10.2 (2366.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.76%
Min EPS beat(2)-40.06%
Max EPS beat(2)-15.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.5%
Min Revenue beat(2)-55.88%
Max Revenue beat(2)26.87%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.3
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.03
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.32%
ROE -143.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.7%
FCFM N/A
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.83%
Cap/Sales 121.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.99
Altman-Z -6.72
F-Score3
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)351.08%
Cap/Depr(5y)283.29%
Cap/Sales(3y)138.98%
Cap/Sales(5y)87.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A
EBIT growth 1Y-45.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.4%
OCF growth 3YN/A
OCF growth 5YN/A

NIGHTHAWK BIOSCIENCES INC / NHWK FAQ

What is the ChartMill fundamental rating of NIGHTHAWK BIOSCIENCES INC (NHWK) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NHWK.


What is the valuation status for NHWK stock?

ChartMill assigns a valuation rating of 0 / 10 to NIGHTHAWK BIOSCIENCES INC (NHWK). This can be considered as Overvalued.


How profitable is NIGHTHAWK BIOSCIENCES INC (NHWK) stock?

NIGHTHAWK BIOSCIENCES INC (NHWK) has a profitability rating of 1 / 10.


What is the financial health of NIGHTHAWK BIOSCIENCES INC (NHWK) stock?

The financial health rating of NIGHTHAWK BIOSCIENCES INC (NHWK) is 0 / 10.